Complementary effects of interleukin-15 and alpha interferon induce immunity in hepatitis B virus transgenic mice

Journal of Virology

Volumn 90, Issue 19, 2016, Pages 8563-8574

  Di Scala, Marianna ^a,b   Otano, Itziar ^c   Gil Fariña, Irene ^a   Vanrell, Lucia ^a   Hommel, Mirja ^a   Olagüe, Cristina ^a,b   Vales, Africa ^a,b   Galarraga, Miguel ^a   Guembe, Laura ^a,b   de Solorzano, Carlos Ortiz ^a,b   Ghosh, Indrajit ^d   Maini, Mala K ^c   Prieto, Jesús ^a,b,e,f   González Aseguinolaza, Gloria ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IdiSNA Navarra Institute for Health Research   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; INTERLEUKIN 15; DRUG CARRIER; HEPATITIS B ANTIBODY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CONTROLLED STUDY; GENE TRANSFER; HEPATITIS B; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; VIRUS LOAD; ADENOVIRIDAE; ANIMAL; BLOOD; CHRONIC HEPATITIS B; DISEASE MODEL; GENE THERAPY; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY; LIVER; TRANSGENIC MOUSE; TREATMENT OUTCOME; VIROLOGY;

ADENOVIRIDAE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; GENETIC THERAPY; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; INTERFERON-ALPHA; INTERLEUKIN-15; LIVER; MICE, TRANSGENIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84990189194     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01030-16     Document Type: Article

References (47)

1. Trepo C, Chan HL, Lok A. 2014. Hepatitis B virus infection. Lancet 384:2053-2063. http://dx.doi.org/10.1016/S0140-6736(14)60220-8
2. Guidotti LG, Chisari FV. 2006. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1:23-61. http://dx.doi.org/10.1146/annurev.pathol.1.110304.100230
3. Rehermann B, Nascimbeni M. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5:215-229. http://dx.doi.org/10.1038/nri1573
4. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C. 2007. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81:4215-4225. http://dx.doi.org/10.1128/JVI.02844-06
5. Maier H, Isogawa M, Freeman GJ, Chisari FV. 2007. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 178:2714-2720. http://dx.doi.org/10.4049/jimmunol.178.5.2714
6. Degasperi E, Vigano M, Aghemo A, Lampertico P, Colombo M. 2013. PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history. Expert Rev Anti Infect Ther 11:459-474. http://dx.doi.org/10.1586/eri.13.37
7. Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, Panno AM, Bernardi M, Brander C, Bihl F, Andreone P, Maini MK. 2013. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 58: 225-233. http://dx.doi.org/10.1016/j.jhep.2012.09.029
8. Penna A, Laccabue D, Libri I, Giuberti T, Schivazappa S, Alfieri A, Mori C, Canetti D, Lampertico P, Vigano M, Colombo M, Loggi E, Missale G, Ferrari C. 2012. Peginterferon-alpha does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. J Hepatol 56:1239-1246. http://dx.doi.org/10.1016/j.jhep.2011.12.032
9. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Huser N, Durantel D, Liang TJ, Munk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. 2014. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343:1221-1228. http://dx.doi.org/10.1126/science.1243462
10. Markova AA, Mihm U, SchlaphoffV, Lunemann S, Filmann N, Bremer B, Berg T, Sarrazin C, Zeuzem S, Manns MP, Cornberg M, Herrmann E, Wedemeyer H. 2014. PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C. PLoS One 9:e94512. http://dx.doi.org/10.1371/journal.pone.0094512
11. Jayaraman A, Jackson DJ, Message SD, Pearson RM, Aniscenko J, Caramori G, Mallia P, Papi A, Shamji B, Edwards M, Westwick J, Hansel T, Stanciu LA, Johnston SL, Bartlett NW. 2014. IL-15 complexes induce NK-and T-cell responses independent of type I IFN signaling during rhinovirus infection. Mucosal Immunol 7:1151-1164. http://dx.doi.org/10.1038/mi.2014.2
12. Hervas-Stubbs S, Mancheno U, Riezu-Boj JI, Larraga A, Ochoa MC, Alignani D, Alfaro C, Morales-Kastresana A, Gonzalez I, Larrea E, Pircher H, Le Bon A, Lopez-Picazo JM, Martin-Algarra S, Prieto J, Melero I. 2012. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy. J Immunol 189:3299-3310. http://dx.doi.org/10.4049/jimmunol.1102495
13. Schluns KS, Williams K, Ma A, Zheng XX, Lefrancois L. 2002. Requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol 168:4827-4831. http://dx.doi.org/10.4049/jimmunol.168.10.4827
14. Huntington ND. 2014. The unconventional expression of IL-15 and its role in NK cell homeostasis. Immunol Cell Biol 92:210-213. http://dx.doi.org/10.1038/icb.2014.1
15. Van Belle TL, Dooms H, Boonefaes T, Wei XQ, Leclercq G, Grooten J. 2012. IL-15 augments TCR-induced CD4+ T cell expansion in vitro by inhibiting the suppressive function of CD25 high CD4+ T cells. PLoS One 7:e45299. http://dx.doi.org/10.1371/journal.pone.0045299
16. Chen XL, Bobbala D, Cepero Donates Y, Mayhue M, Ilangumaran S, Ramanathan S. 2014. IL-15 trans-presentation regulates homeostasis of CD4+ T lymphocytes. Cell Mol Immunol 11:387-397. http://dx.doi.org/10.1038/cmi.2014.13
17. Teague RM, Sather BD, Sacks JA, Huang MZ, Dossett ML, Morimoto J, Tan X, Sutton SE, Cooke MP, Ohlen C, Greenberg PD. 2006. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 12:335-341. http://dx.doi.org/10.1038/nm1359
18. DePaolo RW, Abadie V, Tang F, Fehlner-Peach H, Hall JA, Wang W, Marietta EV, Kasarda DD, Waldmann TA, Murray JA, Semrad C, Kupfer SS, Belkaid Y, Guandalini S, Jabri B. 2011. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 471:220-224. http://dx.doi.org/10.1038/nature09849
19. Yin W, Xu L, Sun R, Wei H, Tian Z. 2012. Interleukin-15 suppresses hepatitis B virus replication via IFN-γ production in a C57BL/6 mouse model. Liver Int 32:1306-1314. http://dx.doi.org/10.1111/j.1478-3231.2012.02773.x
20. Guidotti LG, Matzke B, Schaller H, Chisari FV. 1995. High-level hepatitis B virus replication in transgenic mice. J Virol 69:6158-6169
21. Inuzuka T, Takahashi K, Chiba T, Marusawa H. 2014. Mouse models of hepatitis B virus infection comprising host-virus immunologic interactions. Pathogens 3:377-389. http://dx.doi.org/10.3390/pathogens3020377
22. Shimizu Y, Guidotti LG, Fowler P, Chisari FV. 1998. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 161:4520-4529
23. Buchmann P, Dembek C, Kuklick L, Jager C, Tedjokusumo R, von Freyend MJ, Drebber U, Janowicz Z, Melber K, Protzer U. 2013. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 31:1197-1203. http://dx.doi.org/10.1016/j.vaccine.2012.12.074
24. Di Scala M, Gil-Farina I, Vanrell L, Sanchez-Bayona R, Alignani D, Olague C, Vales A, Berraondo P, Prieto J, Gonzalez-Aseguinolaza G. 2015. Chronic exposure to IFNα drives medullar lymphopoiesis towards T-cell differentiation in mice. Haematologica 100:1014-1022. http://dx.doi.org/10.3324/haematol.2014
25. Gil-Farina I, Di Scala M, Vanrell L, Olague C, Vales A, High KA, Prieto J, Mingozzi F, Gonzalez-Aseguinolaza G. 2013. IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression. PLoS One 8:e67748. http://dx.doi.org/10.1371/journal.pone.0067748
26. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, Schreiber RD, de la Torre JC, Oldstone MB. 2013. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340:207-211. http://dx.doi.org/10.1126/science.1235214
27. Rehermann B. 2015. Natural killer cells in viral hepatitis. Cell Mol Gastroenterol Hepatol 1:578-588. http://dx.doi.org/10.1016/j.jcmgh.2015.09.004
28. Huang YH, Fang CC, Tsuneyama K, Chou HY, Pan WY, Shih YM, Wu PY, Chen Y, Leung PS, Gershwin ME, Tao MH. 2011. A murine model of hepatitis B-associated hepatocellular carcinoma generated by adenoassociated virus-mediated gene delivery. Int J Oncol 39:1511-1519. http://dx.doi.org/10.3892/ijo.2011.1145
29. Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, Fauci AS. 2008. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 181:6738-6746. http://dx.doi.org/10.4049/jimmunol.181.10.6738
30. Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, Honjo T. 2011. IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 186:2772-2779. http://dx.doi.org/10.4049/jimmunol.1003208
31. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, Aronow BJ, Karp CL, Brooks DG. 2013. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340: 202-207. http://dx.doi.org/10.1126/science.1235208
32. Francisco LM, Sage PT, Sharpe AH. 2010. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219-242. http://dx.doi.org/10.1111/j.1600-065X.2010.00923.x
33. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. 2008. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704. http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331
34. Wherry EJ, Kurachi M. 2015. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15:486-499. http://dx.doi.org/10.1038/nri3862
35. Miyagawa F, Tagaya Y, Kim BS, Patel HJ, Ishida K, Ohteki T, Waldmann TA, Katz SI. 2008. IL-15 serves as a costimulator in determining the activity of autoreactive CD8 T cells in an experimental mouse model of graft-versus-host-like disease. J Immunol 181:1109-1119. http://dx.doi.org/10.4049/jimmunol.181.2.1109
36. Berraondo P, Di Scala M, Korolowicz K, Thampi LM, Otano I, Suarez L, Fioravanti J, Aranda F, Ardaiz N, Yang J, Kallakury BV, Tucker RD, Vasquez M, Menne S, Prieto J, Gonzalez-Aseguinolaza G. 2015. Liverdirected gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. J Hepatol 63:329-336. http://dx.doi.org/10.1016/j.jhep.2015.02.048
37. Backes S, Jager C, Dembek CJ, Kosinska AD, Bauer T, Stephan AS, Dislers A, Mutwiri G, Busch DH, Babiuk LA, Gasteiger G, Protzer U. 2016. Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice. Vaccine 34:923-932. http://dx.doi.org/10.1016/j.vaccine.2015.12.060
38. Burrell CJ, Gowans EJ, Marmion BP. 1985. High levels of cytoplasmic hepatitis B core antigen as reliable marker of HBV DNA replication. Lancet i:454-455
39. Gowans EJ, Burrell CJ, Jilbert AR, Marmion BP. 1985. Cytoplasmic (but not nuclear) hepatitis B virus (HBV) core antigen reflects HBV DNA synthesis at the level of the infected hepatocyte. Intervirology 24:220-225. http://dx.doi.org/10.1159/000149646
40. Marshall HD, Prince AL, Berg LJ, Welsh RM. 2010. IFN-αβ and self-MHCdivert CD8 T cells into a distinct differentiation pathway characterized by rapid acquisition of effector functions. J Immunol 185:1419-1428. http://dx.doi.org/10.4049/jimmunol.1001140
41. Stelma F, de Niet A, Tempelmans Plat-Sinnige MJ, Jansen L, Takkenberg RB, Reesink HW, Kootstra NA, van Leeuwen EM. 2015. Natural killer cell characteristics in patients with chronic hepatitis B virus (HBV) infection are associated with HBV surface antigen clearance after combination treatment with pegylated interferon alfa-2a and adefovir. J Infect Dis 212:1042-1051. http://dx.doi.org/10.1093/infdis/jiv180
42. + T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol 61:1212-1219. http://dx.doi.org/10.1016/j.jhep.2014.07.005
43. Tzeng HT, Tsai HF, Liao HJ, Lin YJ, Chen L, Chen PJ, Hsu PN. 2012. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One 7:e39179. http://dx.doi.org/10.1371/journal.pone.0039179
44. Vo M, Holz LE, Wong YC, English K, Benseler V, McGuffog C, Azuma M, McCaughan GW, Bowen DG, Bertolino P. 2016. Effector T cell function rather than survival determines extent and duration of hepatitis in mice. J Hepatol 64:1327-1133. http://dx.doi.org/10.1016/j.jhep.2016.01.040
45. + T cells in HIV-1 infection. J Clin Invest 126:2745-2756. http://dx.doi.org/10.1172/JCI85996
46. Sandalova E, Laccabue D, Boni C, Tan AT, Fink K, Ooi EE, Chua R, Shafaeddin Schreve B, Ferrari C, Bertoletti A. 2010. Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans. PLoS Pathog 6:e1001051. http://dx.doi.org/10.1371/journal.ppat.1001051
47. Abad X, Razquin N, Abad A, Fortes P. 2010. Combination of RNA interference and U1 inhibition leads to increased inhibition of gene expression. Nucleic Acids Res 38:e136. http://dx.doi.org/10.1093/nar/gkq299